MCID: GRV001
MIFTS: 59

Graves' Disease malady

Categories: Rare diseases, Endocrine diseases, Immune diseases

Aliases & Classifications for Graves' Disease

Aliases & Descriptions for Graves' Disease:

Name: Graves' Disease 12 50 25 14
Graves Disease 12 25 29 52 42 14 69
Exophthalmic Goiter 12 50 25
Toxic Diffuse Goiter 25 69
Basedow's Disease 12 25
Basedow Disease 50 25
Autoimmune Hyperthyroidism 25
Toxic Multinodular Goiter 69
Graves' Hyperthyroidism 50
Grave's Disease 12
Parry Disease 50

Classifications:



Summaries for Graves' Disease

NIH Rare Diseases : 50 graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). it is caused by an abnormal immune system response that causes the thyroid gland to produce too much thyroid hormones. graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. however, the disorder may occur at any age and may affect males as well. treatment may include radioiodine therapy, antithyroid drugs, and/or thyroid surgery. last updated: 4/21/2015

MalaCards based summary : Graves' Disease, also known as graves disease, is related to rheumatoid arthritis and autoimmune hemolytic anemia. An important gene associated with Graves' Disease is SLC25A16 (Solute Carrier Family 25 Member 16), and among its related pathways/superpathways are PAK Pathway and Cytokine Signaling in Immune system. The drugs Propylthiouracil and Bimatoprost have been mentioned in the context of this disorder. Affiliated tissues include thyroid, t cells and skin, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Genetics Home Reference : 25 Graves disease is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. In people with Graves disease, the thyroid is overactive and makes more hormones than the body needs. The condition usually appears in mid-adulthood, although it may occur at any age.

Disease Ontology : 12 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.

Wikipedia : 71 Graves\' disease, also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid.... more...

Related Diseases for Graves' Disease

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves' Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
id Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 29.1 CTLA4 HLA-DQA1 ICAM1 IFNG IL2RA IL4
2 autoimmune hemolytic anemia 29.0 CTLA4 FASLG IFNG SERPINA7 TG TPO
3 graves disease 1 12.1
4 graves disease 2 11.9
5 hyperthyroidism 11.2
6 exophthalmos 11.1
7 digeorge syndrome 11.1
8 autoimmune thyroid disease 3 10.9
9 myopathy - thyrotoxic 10.9
10 cln4 disease 10.8
11 thyrotoxic periodic paralysis 1 10.7
12 hyperthyroidism, nonautoimmune 10.7
13 thyrotoxic periodic paralysis 2 10.7
14 autoimmune thyroid disease 2 10.7
15 thyroiditis 10.7
16 fibrous meningioma 10.3 TG TPO
17 neuhauser daly magnelli syndrome 10.3 TG TPO TSHR
18 adenocarcinoma of penis 10.3 CTLA4 HLA-DQA1
19 exanthema subitum 10.3 TG TPO TSHR
20 peritoneal serous papillary adenocarcinoma 10.3 TG TPO TSHR
21 commensal bacterial infectious disease 10.3 TG TPO TSHR
22 myoglobinuria recurrent 10.3 IFNG IL4
23 hypermobility syndrome 10.3 CTLA4 PTPN22 TPO
24 goiter 10.3
25 conjunctival deposit 10.3 CTLA4 TG TPO TSHR
26 non-amyloid monoclonal immunoglobulin deposition disease 10.3 IL2RA PTPN22
27 choreoathetosis, hypothyroidism, and neonatal respiratory distress 10.3 TG TPO TSHR
28 acute gonococcal prostatitis 10.2 CTLA4 IFNG IL4
29 nail disorder, nonsyndromic congenital, 7 10.2 CTLA4 PTPN22 TPO
30 tenosynovitis of foot and ankle 10.2 TG TPO TSHR
31 abnormal retinal correspondence 10.2 CTLA4 IFNG IL4
32 tick paralysis 10.2 ICAM1 TG TPO
33 autoimmune disease of skin and connective tissue 10.2 CTLA4 HLA-DQA1 IFNG
34 neuronopathy, distal hereditary motor, type viia 10.2 SERPINA7 TG TSHR
35 myxedema 10.2
36 asymptomatic neurosyphilis 10.2 IFNG IL2RA IL4
37 blue toe syndrome 10.2 CD40 IFNG IL4
38 muscular dystrophy-dystroglycanopathy , type a, 10 10.2 DIO2 LMOD1 TG TPO TSHR
39 hallucinogen dependence 10.2 CD40 IFNG IL4
40 cutaneous fibrous histiocytoma 10.2 IFNG IL2RA IL4
41 isolated klippel-feil syndrome 10.2 IFNG IL2RA IL4
42 nodular prostate 10.2 ICAM1 TG TPO TSHR
43 central nervous system origin vertigo 10.2 IFNG IL2RA IL4
44 hypothyroidism 10.2
45 hemangioma of intra-abdominal structure 10.2 FASLG IFNG
46 myiasis 10.1 IFNG IL2RA IL4
47 background diabetic retinopathy 10.1 SERPINA7 TG TPO TSHR
48 krabbe disease 10.1 SERPINA7 TG TPO TSHR
49 mixed eosinophil-basophil adenoma 10.1 SERPINA7 TG TPO TSHR
50 hypothyroidism, congenital, nongoitrous, 1 10.1 SERPINA7 TG TPO TSHR

Graphical network of the top 20 diseases related to Graves' Disease:



Diseases related to Graves' Disease

Symptoms & Phenotypes for Graves' Disease

MGI Mouse Phenotypes related to Graves' Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.25 CD40 CTLA4 DIO2 FASLG HLA-DQA1 ICAM1
2 hematopoietic system MP:0005397 10.24 IL16 IL2RA IL4 PTPN22 TG TPO
3 homeostasis/metabolism MP:0005376 10.17 FGFR1OP ICAM1 IFNG IGF1R IL2RA IL4
4 immune system MP:0005387 10.1 CD40 CTLA4 FASLG FGFR1OP HLA-DQA1 ICAM1
5 digestive/alimentary MP:0005381 10.09 PTPN22 CTLA4 DIO2 FASLG ICAM1 IFNG
6 respiratory system MP:0005388 9.7 CTLA4 FASLG IFNG IGF1R IL2RA IL4
7 skeleton MP:0005390 9.61 IL4 TPO TSHR CD40 CTLA4 DIO2
8 vision/eye MP:0005391 9.23 FASLG FGFR1OP ICAM1 IFNG IL2RA IL4

Drugs & Therapeutics for Graves' Disease

Drugs for Graves' Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
3
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
4
Timolol Approved Phase 4 26839-75-8 33624 5478
5
Travoprost Approved Phase 4 157283-68-6 5282226
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
9
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
13
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
14
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
17
Ephedrine Approved Phase 4 299-42-3 9294
18
Pseudoephedrine Approved Phase 4 90-82-4 7028
19
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
22
Armodafinil Approved, Investigational Phase 4,Phase 3 112111-43-0
23
Modafinil Approved, Investigational Phase 4,Phase 3 68693-11-8 4236
24
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
25
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
26
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
27
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
31
Maleic acid Experimental Phase 4 110-16-7 444266
32 Antimetabolites Phase 4,Phase 3,Phase 2
33 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
35 Hormones Phase 4,Phase 2,Phase 3,Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
37 Adrenergic Agents Phase 4,Phase 1
38 Adrenergic Antagonists Phase 4
39 Adrenergic beta-Antagonists Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Antihypertensive Agents Phase 4,Phase 3
42 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Ophthalmic Solutions Phase 4,Phase 2
44 Tetrahydrozoline Phase 4,Phase 2
45 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
48 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
50 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 221)
id Name Status NCT ID Phase
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4
2 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Unknown status NCT01927406 Phase 4
3 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4
4 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
5 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4
6 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4
7 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4
8 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4
9 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4
10 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4
11 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
12 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4
13 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4
14 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4
15 Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans Completed NCT02117206 Phase 4
16 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
17 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4
18 A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE) Completed NCT00443443 Phase 4
19 A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) Completed NCT00096928 Phase 4
20 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4
21 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
22 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4
23 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4
24 Cryoanalgesia vs. Epidural in the Nuss Procedure Recruiting NCT02721017 Phase 4
25 Effects of Statins in Graves' Orbitopathy (GO) in Hypercholesterolemic Patients Not yet recruiting NCT03110848 Phase 4
26 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4
27 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4
28 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4
29 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
30 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3
31 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Unknown status NCT02155049 Phase 3
32 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3
33 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
34 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3
35 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3
36 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3
37 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease Completed NCT01689233 Phase 3
38 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3
39 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Completed NCT00193596 Phase 3
40 Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients Completed NCT02357771 Phase 3
41 Phase IIIB Switching From Intravenous to Subcutaneous Study Completed NCT00663702 Phase 3
42 Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon Completed NCT01542788 Phase 3
43 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection Completed NCT01641640 Phase 3
44 Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) Completed NCT01604850 Phase 3
45 Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) Completed NCT01100684 Phase 3
46 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
47 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3
48 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
49 Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens Completed NCT01096615 Phase 3
50 Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia Completed NCT00803023 Phase 3

Search NIH Clinical Center for Graves' Disease

Cochrane evidence based reviews: graves disease

Genetic Tests for Graves' Disease

Genetic tests related to Graves' Disease:

id Genetic test Affiliating Genes
1 Graves' Disease 29

Anatomical Context for Graves' Disease

MalaCards organs/tissues related to Graves' Disease:

39
Thyroid, T Cells, Skin, Eye, Heart, Bone, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Graves' Disease:

18
Thyroid Gl

Publications for Graves' Disease

Articles related to Graves' Disease:

(show top 50) (show all 1492)
id Title Authors Year
1
Common phenotype and different non-HLA genes in Graves' disease and alopecia areata. ( 27810496 )
2017
2
Graves' Disease. ( 28076710 )
2017
3
Graves' Disease. ( 28079342 )
2017
4
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
5
Protein oxidation and autoantibodies' reactivity against malondialdehyde and hydrogen peroxide-modified thyroid antigens in plasma of patients with Graves' disease and Hashimoto Thyroiditis. ( 28431875 )
2017
6
MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves' disease and its significance. ( 28219358 )
2017
7
Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium ((99m)Tc) scintigraphy. ( 27553050 )
2016
8
Proteomic analysis reveals aberrant expression of CALR and HSPA5 in thyroid tissues of Graves' disease. ( 27566407 )
2016
9
Enhancement of CD4(+) T cell response and survival via coexpressed OX40/OX40L in Graves' disease. ( 27107937 )
2016
10
Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease. ( 26676335 )
2016
11
The efficacy of immunosuppressive treatment of Graves' orbitopathy is not affected by previous anti-thyroid drugs or by radioiodine therapy of Graves' disease. ( 28042648 )
2016
12
Hyperthyroidism and Graves' disease: Is an ultrasound examination needed? ( 27867894 )
2016
13
Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis. ( 27465319 )
2016
14
Circulating microRNAs in Graves' Disease in Relation to Clinical Activity. ( 27610819 )
2016
15
Thyroidectomy for Graves' disease in children: Indications and complications. ( 27113266 )
2016
16
Isolated Adrenocorticotropin Deficiency Concomitant with Graves' Disease: A Case Report and Literature Review. ( 27629962 )
2016
17
Management of Fetal and Neonatal Graves' Disease. ( 27978517 )
2016
18
Myasthenia gravis accompanied by Graves' disease, thyrotoxic hypokalemic periodic paralysis and thymic hyperplasia. ( 27381127 )
2016
19
Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy. ( 27601953 )
2016
20
Influence of thyroid volume on the effect of methimazole in Japanese subjects with mild Graves' disease. ( 27601286 )
2016
21
Association of KCNJ2 Genetic Variants with Susceptibility to Thyrotoxic Periodic Paralysis in Patients with Graves' Disease. ( 28008586 )
2016
22
Von Willebrand factor and coagulation factor VIII in Moyamoya disease associated with Graves' disease: A case report. ( 27882137 )
2016
23
Concurrent Pemphigus Foliaceus and Graves' Disease. ( 27981628 )
2016
24
Increased pertechnetate and radioiodine uptake in the thyroid gland with subacute thyroiditis and concurrent Graves' disease. ( 26929941 )
2016
25
Superior Mesenteric Artery Syndrome Complicated by Diabetic Ketoacidosis and Graves' Disease in Slowly Progressive Insulin Dependent Diabetes Mellitus (SPIDDM): A Case Report and a Review of the Literature. ( 27477411 )
2016
26
Genetic association of Fc receptor-like glycoprotein with susceptibility to Graves' disease in a Chinese Han population. ( 26321232 )
2016
27
A case of hypercalcaemic crisis secondary to coexistence of primary hyperparathyroidism and Graves' disease. ( 27941175 )
2016
28
Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease: Reply. ( 27189073 )
2016
29
Hyperthyroidism Improves the Pathological Condition of Nonalcoholic Steatohepatitis: A Case of Nonalcoholic Steatohepatitis with Graves' Disease. ( 27477408 )
2016
30
Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans. ( 27913646 )
2016
31
Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. ( 26996584 )
2016
32
Sanguineous Pericardial Effusion and Cardiac Tamponade in the Setting of Graves' Disease: Report of a Case and Review of Previously Reported Cases. ( 27446216 )
2016
33
Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves' disease. ( 26786783 )
2016
34
Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any). ( 27319009 )
2016
35
Intracranial Abscess Presenting as Periorbital Edema of Graves Disease. ( 27159867 )
2016
36
Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves' disease after 131Iodine treatment. ( 27618833 )
2016
37
CD40 SIGNALING IN GRAVES' DISEASE IS MEDIATED THROUGH CANONICAL AND NON-CANONICAL THYROIDAL NF-I_B ACTIVATION. ( 27929668 )
2016
38
Gene Map of the HLA Region, Graves' Disease and Hashimoto Thyroiditis, and Hematopoietic Stem Cell Transplantation. ( 26791860 )
2016
39
Differentiating Graves' disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. ( 27570620 )
2016
40
The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds. ( 27090092 )
2016
41
GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES' DISEASE. ( 27540885 )
2016
42
Current trends in antithyroid drug treatment of Graves' disease. ( 27615550 )
2016
43
Risk Factors of Lymphnode Metastasis in Patients with Thyroid <br/>Papillary Carcinoma Associated with Graves Disease. ( 27825413 )
2016
44
Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study. ( 27392116 )
2016
45
Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease. ( 27602020 )
2016
46
Controversies in the management of Graves' disease in children. ( 27153850 )
2016
47
FREQUENCY OF FLAME SENSOR ACTIVATION IN PUBLIC PLACES AFTER ADMINISTRATION OF RADIOACTIVE IODINE TO TREAT GRAVES' DISEASE: A RECENT SURVEY. ( 27124691 )
2016
48
Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations. ( 27099839 )
2016
49
AIRE genetic variants and predisposition to polygenic autoimmune disease: The case of Graves' disease and a systematic literature review. ( 27266815 )
2016
50
The characteristics of osteoporotic patients in Graves' disease patients newly diagnosed after menopause: a prospective observational study. ( 27600197 )
2016

Variations for Graves' Disease

Expression for Graves' Disease

Search GEO for disease gene expression data for Graves' Disease.

Pathways for Graves' Disease

Pathways related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 CD40 FASLG IGF1R IL16 IL2RA IL4
2
Show member pathways
13.22 CD40 FASLG HLA-DQA1 ICAM1 IFNG IL16
3
Show member pathways
12.63 FASLG HLA-DQA1 ICAM1 IFNG IL2RA IL4
4
Show member pathways
12.53 CD40 HLA-DQA1 IFNG IL2RA IL4
5 12.35 CD40 HLA-DQA1 ICAM1 IL2RA
6
Show member pathways
12.34 SERPINA7 TG TPO TSHR
7 12.34 CTLA4 FASLG IFNG IL2RA IL4 PTPN22
8
Show member pathways
12.31 CD40 CTLA4 HLA-DQA1 IL2RA
9
Show member pathways
12.24 DIO2 ICAM1 IFNG IL4
10 12.2 CD40 HLA-DQA1 ICAM1 IFNG
11
Show member pathways
12.14 CD40 HLA-DQA1 IFNG IL4
12
Show member pathways
12.1 CD40 CTLA4 FASLG HLA-DQA1 ICAM1 IFNG
13 11.99 CD40 CTLA4 HLA-DQA1 ICAM1
14 11.81 HLA-DQA1 IL2RA IL4
15
Show member pathways
11.79 FASLG IFNG IL2RA IL4
16 11.72 ICAM1 IFNG IL4
17 11.7 IFNG IL2RA IL4
18 11.66 CTLA4 HLA-DQA1 ICAM1 IFNG
19 11.63 CTLA4 HLA-DQA1 PTPN22
20
Show member pathways
11.6 FASLG IL2RA IL4
21
Show member pathways
11.55 FASLG IFNG IL2RA
22
Show member pathways
11.43 CTLA4 FASLG IFNG IL2RA IL4
23 11.42 CD40 ICAM1 IFNG
24 11.4 IFNG IL2RA IL4
25 11.36 FASLG ICAM1 IFNG
26
Show member pathways
11.27 FASLG IFNG IL2RA
27 11.2 FASLG ICAM1 IFNG
28 11.2 CD40 CTLA4 ICAM1 IL2RA IL4
29 11.08 CD40 IFNG IL2RA IL4
30 10.28 TG TPO TSHR

GO Terms for Graves' Disease

Cellular components related to Graves' Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 CD40 FASLG ICAM1 IFNG IL16 IL4
2 integral component of plasma membrane GO:0005887 9.76 CD40 CTLA4 FASLG HLA-DQA1 ICAM1 IGF1R
3 cell surface GO:0009986 9.43 CD40 FASLG ICAM1 IL2RA TPO TSHR
4 external side of plasma membrane GO:0009897 9.17 CD40 CTLA4 FASLG ICAM1 IFNG IL2RA

Biological processes related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 CD40 CTLA4 HLA-DQA1 IL2RA PTPN22
2 regulation of immune response GO:0050776 9.81 CD40 ICAM1 IFNG IL4
3 positive regulation of cell proliferation GO:0008284 9.8 FASLG FGFR1OP IFNG IGF1R IL4 TSHR
4 response to lipopolysaccharide GO:0032496 9.76 CD40 FASLG ICAM1 PTPN22
5 interferon-gamma-mediated signaling pathway GO:0060333 9.7 HLA-DQA1 ICAM1 IFNG
6 positive regulation of T cell proliferation GO:0042102 9.67 IFNG IL2RA IL4
7 positive regulation of endothelial cell apoptotic process GO:2000353 9.58 CD40 FASLG
8 negative regulation of immune response GO:0050777 9.58 CTLA4 IL2RA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 CD40 IFNG IL4
10 thyroid hormone generation GO:0006590 9.57 DIO2 TPO
11 positive regulation of tyrosine phosphorylation of Stat1 protein GO:0042511 9.56 CD40 IFNG
12 positive regulation of chemokine biosynthetic process GO:0045080 9.54 IFNG IL4
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IFNG IL4
14 thyroid hormone metabolic process GO:0042403 9.43 DIO2 TG
15 defense response to protozoan GO:0042832 9.43 CD40 IFNG IL4
16 inflammatory cell apoptotic process GO:0006925 9.37 FASLG IFNG
17 hormone biosynthetic process GO:0042446 9.33 DIO2 TG TPO
18 immune response GO:0006955 9.28 CD40 CTLA4 FASLG HLA-DQA1 IFNG IGF1R
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.13 CD40 IFNG IL4

Molecular functions related to Graves' Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 FASLG IFNG IL16 IL4

Sources for Graves' Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....